Top

Published in:

01-07-2015 | Letter to the Editor

Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan

Authors: Muhammad U. Rashid, Noor Muhammad, Faiz A. Khan, Ute Hamann

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Excerpt

Breast cancer is the most common cancer among women worldwide. Approximately 5–10 % of breast cancers are hereditary, and caused by monoallelic germ line mutations in high-, moderate-, and low-penetrance breast cancer susceptibility genes. Several of these genes such as BRCA1, BRCA2, PALB2, BRIP1, and genes of the RAD51 family play an important role in maintenance of genomic stability and are functionally linked with homologous recombination-mediated DNA damage repair. Breast cancer susceptibility is connected with the Fanconi anemia (FA) pathway, since biallelic mutations in at least four genes, BRCA2 (FANCD1) [1], PALB2 (FANCN) [2], BRIP1 (FANCJ) [3], and RAD51C (FANCO) [4] have been shown to also cause FA. …

Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609CrossRefPubMed

Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161CrossRefPubMed

Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933CrossRefPubMed

Vaz F, Hanenberg H, Schuster B et al (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42:406–409CrossRefPubMed

Kiiski JI, Pelttari LM, Khan S et al (2014) Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A 111:15172–15177CrossRefPubMedPubMedCentral

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U (2014) Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Res Treat 145:775–784CrossRefPubMed

Rashid MU, Zaidi A, Torres D et al (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119:2832–2839CrossRefPubMed

Garcia MJ, Fernandez V, Osorio A et al (2009) Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis 30:1898–1902CrossRefPubMed

Gracia-Aznarez FJ, Fernandez V, Pita G et al (2013) Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 8:e55681CrossRefPubMedPubMedCentral

10.

Akbari MR, Malekzadeh R, Lepage P et al (2011) Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum Genet 129:573–582CrossRefPubMed

Title: Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan
Authors: Muhammad U. Rashid
Noor Muhammad
Faiz A. Khan
Ute Hamann
Publication date: 01-07-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3457-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients

Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients

The association between breast cancer and thyroid cancer: a meta-analysis

Letter to the Editor Re: Bundred et al. “Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer”

Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer